IRWD - Ironwood Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Boston,
United States
Type: Equity
IRWD price evolution
IRWD
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $92.15 | $110.95 | $176.11 | $741.59 |
| Short term investments | ||||
| Net receivables | $129.12 | $124.55 | $118.99 | $115.75 |
| Inventory | ||||
| Total current assets | $233.29 | $253.61 | $317.6 | $866.37 |
| Long term investments | $0.51 | $0.51 | $0.48 | |
| Property, plant & equipment | $18.17 | $18.59 | $19.2 | $19.69 |
| Goodwill & intangible assets | $3.68 | $3.89 | $4.1 | |
| Total noncurrent assets | $237.78 | $270.45 | $285.62 | $288.9 |
| Total investments | $0.51 | $0.51 | $0.48 | |
| Total assets | $471.07 | $524.06 | $603.22 | $1155.28 |
| Current liabilities | ||||
| Accounts payable | $7.83 | $4.7 | $3.5 | $0.12 |
| Deferred revenue | ||||
| Short long term debt | $202.69 | $202.43 | $202.18 | $3.08 |
| Total current liabilities | $276.1 | $280.58 | $305.39 | $23.84 |
| Long term debt | $512.85 | $538.22 | $613.57 | $412.76 |
| Total noncurrent liabilities | $541.27 | $569.16 | $644.61 | $424.58 |
| Total debt | $715.54 | $740.65 | $815.75 | $415.84 |
| Total liabilities | $817.37 | $849.74 | $950 | $448.43 |
| Shareholders' equity | ||||
| Retained earnings | -$1698.62 | -$1697.53 | -$1712.85 | -$650.66 |
| Other shareholder equity | -$3.03 | -$0.75 | ||
| Total shareholder equity | -$346.3 | -$323.22 | -$345.7 | $706.85 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $92.15 | $657.45 | $621.38 | $364.3 |
| Short term investments | ||||
| Net receivables | $129.12 | $115.46 | $138.04 | $145.75 |
| Inventory | ||||
| Total current assets | $233.29 | $780.63 | $745.23 | $495.84 |
| Long term investments | $0.48 | $0.48 | $0.48 | |
| Property, plant & equipment | $18.17 | $20.31 | $22.93 | $25.5 |
| Goodwill & intangible assets | $3.68 | |||
| Total noncurrent assets | $237.78 | $319.89 | $381.7 | $63.4 |
| Total investments | $0.48 | $0.48 | $0.48 | |
| Total assets | $471.07 | $1100.52 | $1126.93 | $559.24 |
| Current liabilities | ||||
| Accounts payable | $7.83 | $0.48 | $0.94 | $0.66 |
| Deferred revenue | ||||
| Short long term debt | $202.69 | $3.08 | $121.3 | $3.13 |
| Total current liabilities | $276.1 | $25.52 | $161.7 | $32.17 |
| Long term debt | $512.85 | $396.25 | $355.82 | $462.66 |
| Total noncurrent liabilities | $541.27 | $422.62 | $359.32 | $464.43 |
| Total debt | $715.54 | $415.93 | $477.12 | $465.79 |
| Total liabilities | $817.37 | $448.14 | $521.02 | $496.6 |
| Shareholders' equity | ||||
| Retained earnings | -$1698.62 | -$696.38 | -$937.61 | -$1466.06 |
| Other shareholder equity | -$3.03 | $605.91 | ||
| Total shareholder equity | -$346.3 | $652.38 | $605.91 | $62.64 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $117.55 | $113.74 | $107.38 | $104.06 |
| Cost of revenue | ||||
| Gross Profit | $117.55 | $113.74 | $107.38 | $104.06 |
| Operating activities | ||||
| Research & development | $35.68 | $32.98 | $34.58 | $12.85 |
| Selling, general & administrative | $38.67 | $36.05 | $52.48 | $31.12 |
| Total operating expenses | $79.96 | $73.72 | $1190.52 | $43.96 |
| Operating income | $37.59 | $40.02 | -$1083.14 | $60.1 |
| Income from continuing operations | ||||
| EBIT | $39.44 | $43.14 | -$1074.38 | $67.39 |
| Income tax expense | $32.1 | $17.98 | $13.26 | $20.15 |
| Interest expense | $8.42 | $9.84 | $1.84 | $1.53 |
| Net income | ||||
| Net income | -$1.09 | $15.32 | -$1089.48 | $45.71 |
| Income (for common shares) | -$1.09 | $15.32 | -$1062.19 | $45.71 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $442.74 | $410.6 | $413.75 | $389.52 |
| Cost of revenue | $3.14 | |||
| Gross Profit | $442.74 | $410.6 | $413.75 | $386.39 |
| Operating activities | ||||
| Research & development | $116.08 | $44.27 | $70.41 | $88.06 |
| Selling, general & administrative | $158.31 | $115.99 | $111.13 | $140 |
| Total operating expenses | $1388.16 | $160.26 | $181.49 | $243.45 |
| Operating income | -$945.43 | $250.34 | $232.26 | $142.94 |
| Income from continuing operations | ||||
| EBIT | -$897.12 | $260.02 | $231.81 | $138.34 |
| Income tax expense | $83.49 | $77.36 | -$327.79 | $2.69 |
| Interest expense | $21.63 | $7.6 | $31.15 | $29.48 |
| Net income | ||||
| Net income | -$1002.24 | $175.06 | $528.45 | $106.18 |
| Income (for common shares) | -$1002.24 | $175.06 | $528.45 | $106.18 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$1.09 | $15.32 | -$1089.48 | $45.71 |
| Operating activities | ||||
| Depreciation | $0.51 | $0.51 | $0.27 | $0.29 |
| Business acquisitions & disposals | -$3.98 | -$22.58 | -$999.49 | |
| Stock-based compensation | $8.7 | $7.91 | $8.26 | $7.13 |
| Total cash flows from operations | $35.83 | $32.46 | $34.96 | $80.17 |
| Investing activities | ||||
| Capital expenditures | -$0.21 | -$0.05 | -$0.01 | |
| Investments | ||||
| Total cash flows from investing | -$4.19 | -$22.63 | -$999.49 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1 | $0.01 | $1.37 | $3.98 |
| Net borrowings | -$25.59 | -$75 | $397.7 | |
| Total cash flows from financing | -$50.9 | -$74.99 | $399.07 | $3.98 |
| Effect of exchange rate | -$0.05 | -$0 | ||
| Change in cash and equivalents | -$19.31 | -$65.16 | -$565.46 | $84.14 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$1002.24 | $175.06 | $528.45 | $106.18 |
| Operating activities | ||||
| Depreciation | $1.57 | $1.42 | $1.52 | $3.56 |
| Business acquisitions & disposals | -$1026.05 | |||
| Stock-based compensation | $32.01 | $27.05 | $22.28 | $31.18 |
| Total cash flows from operations | $183.43 | $273.76 | $261.89 | $168.84 |
| Investing activities | ||||
| Capital expenditures | -$0.27 | -$0.14 | -$0.27 | -$1.84 |
| Investments | ||||
| Total cash flows from investing | -$1026.32 | -$0.14 | -$0.27 | -$1.84 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.36 | -$116.85 | -$4.55 | $18.55 |
| Net borrowings | $297.11 | -$120.7 | ||
| Total cash flows from financing | $277.16 | -$237.55 | -$4.55 | $18.55 |
| Effect of exchange rate | -$0.05 | |||
| Change in cash and equivalents | -$565.78 | $36.07 | $257.08 | $185.54 |
News
Fundamentals
| Market cap | $1.24B |
|---|---|
| Enterprise value | $1.86B |
| Shares outstanding | 156.35M |
| Revenue | $442.74M |
|---|---|
| EBITDA | -$922.84M |
| EBIT | -$924.41M |
| Net Income | -$1.03B |
| Revenue Q/Q | 9.66% |
| Revenue Y/Y | N/A |
| P/E ratio | -1.20 |
|---|---|
| EV/Sales | 4.21 |
| EV/EBITDA | -2.02 |
| EV/EBIT | -2.01 |
| P/S ratio | 2.80 |
| P/B ratio | -3.61 |
| Book/Share | -2.20 |
| Cash/Share | 0.59 |
| EPS | -$6.58 |
|---|---|
| ROA | -149.55% |
| ROE | 1.34K% |
| Debt/Equity | -2.36 |
|---|---|
| Net debt/EBITDA | -0.79 |
| Current ratio | 0.84 |
| Quick ratio | 0.84 |